Clinical trials: psoriasis
Psoriasis
Vtama in Psoriasis Patients Being Treated With Biologics.
Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.
- Trial name
- NCT06103695
- Testing
- Tapinarof
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Apical Periodontitis
Association Between Apical Periodontitis and Psoriasis Vulgaris
The aim of the present cross-sectional study is to assess the presence of AP and caries in psoriasis vulgaris individuals and to examine whether these medications influence these oral conditions.
- Trial name
- NCT06436339
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- University of Siena
Plaque Psoriasis
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
This is a phase Ⅲ, randomized, double-blind, placebo-controlled, parallel design, multicenter trial to evaluate the efficacy, safety, tolerability, and immunogenicity of subcutaneous Tildrakizumab in subjects with moderate to…
- Trial name
- NCT05108766
- Testing
- Tildrakizumab 100 mg
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Psoriasis
Assessing Patient Confidence in Biologic Medications
In dermatology, biologic medications are used to treat conditions such as moderate-to-severe psoriasis. These medications generally function to decrease inflammation or disrupt the inflammatory cycle.
- Trial name
- NCT03168347
- Testing
- Anecdotal Evidence, Research Study Evidence, Anecdotal + Research Study Evidence
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Wake Forest University Health Sciences
Plaque Psoriasis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
- Trial name
- NCT02932878
- Testing
- DSXS topical
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants…
- Trial name
- NCT02672852
- Testing
- Risankizumab
- Volunteers
- 507 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
- Trial name
- IXORA-P (NCT02513550)
- Testing
- Ixekizumab
- Where
- 125 sites in United States, Argentina and 12 more
- Volunteers
- 1,257 people
- Sponsor
- Eli Lilly and Company
Arthritis, Psoriatic
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
- Trial name
- STAR (NCT04929210)
- Testing
- Guselkumab
- Where
- 240 sites in United States, Argentina and 24 more
- Volunteers
- 411 people
- Sponsor
- Janssen Research & Development, LLC
Mild-to-moderate Psoriasis Vulgaris
Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
The overall purpose of this study is to support the development of a DLX105 topical formulation for the indication mild to moderate psoriasis vulgaris.
- Trial name
- 2011-00500-15 (NCT01595997)
- Testing
- DLX105
- Where
- 2 sites in Austria, Germany
- Volunteers
- 20 people
- Sponsor
- Delenex Therapeutics AG
Psoriasis
Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis
Dendritic cells (DC) paly a key role in the induction and chronicity of psoriasis by capturing the antigenes and activating the T cell repsonse.
- Trial name
- NCT05399433
- Testing
- Biopsy and venous blood
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Psoriasis
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have been previously enrolled in an applicable Phase 3 psoriasis study.
- Trial name
- POETYK PSO-LTE (NCT04036435)
- Testing
- BMS-986165
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,466 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy of multiple-dose HSK47388 versus placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07158268
- Testing
- HSK47388
- Volunteers
- 220 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Plaque Psoriasis
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT01882647
- Testing
- 000-0551 Lotion, Vehicle Lotion
- Where
- 11 sites in United States
- Volunteers
- 222 people
- Sponsor
- Therapeutics, Inc.
Psoriasis, Stress
12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN
This is a 12-Week, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate to severe psoriasis treated with TEN.
- Trial name
- NCT03511755
- Testing
- Transdermal Electrical Neuromodulator (TEN)
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Thync Global, Inc.
Psoriatic Arthritis, Osteoarthitis
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1/GIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance…
- Conditions
- Psoriatic Arthritis, Osteoarthitis, Knee, Diabetes (DM)
- Trial name
- CARTIZ (NCT07567378)
- Testing
- Tirzepatide
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- JULIO GRANADOS MONTIEL
Psoriasis Vulgaris
A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic…
- Trial name
- NCT03331835
- Testing
- Brodalumab, Fumaric acid esters
- Where
- 30 sites in Germany
- Volunteers
- 210 people
- Sponsor
- LEO Pharma
Psoriasis
Comparative Analysis of Small and Large Plaque Psoriasis
Psoriasis is a chronic, debilitating skin disorder with an estimated prevalence of 2%. Psoriatic skin lesions start with initial pinhead-sized macules and then coalesce into plaques of varying sizes.
- Trial name
- NCT01920906
- Testing
- Skin biopsy and blood test
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Moderate to Severe Plaque Psoriasis
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
This is a multicenter, prospective, observational study of 1516 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of vunakizumab in patients with moderate-to-severe chronic plaque…
- Trial name
- NCT06696417
- Testing
- Drug group：vunakizumab (IL-17A inhibitor)
- Where
- China
- Volunteers
- 1,516 people
- Sponsor
- First Hospital of China Medical University
Rheumatoid Arthritis, Psoriatic Arthritis
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
- Trial name
- NCT01198509
- Testing
- doxycycline, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Moderate to Severe Chronic Plaque Psoriasis
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
This was a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for…
- Trial name
- NCT05388916
- Testing
- Cosentyx
- Where
- 7 sites in China
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.